Drug And Allied Industries
Download Drug And Allied Industries full books in PDF, epub, and Kindle. Read online free Drug And Allied Industries ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
The Role of NIH in Drug Development Innovation and Its Impact on Patient Access
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 103 |
Release | : 2020-01-27 |
Genre | : Medical |
ISBN | : 0309498511 |
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Pharmaceutical Calculations
Author | : Mitchell J. Stoklosa |
Publisher | : |
Total Pages | : 428 |
Release | : 1986 |
Genre | : Medical |
ISBN | : 9780812110074 |
Asian Medical Industries
Author | : Stephan Kloos |
Publisher | : Routledge |
Total Pages | : 329 |
Release | : 2022-02-28 |
Genre | : Medical |
ISBN | : 1000523268 |
This book develops the concept of Asian Medical Industries as a novel perspective on traditional Asian medicines. Complementing and updating existing work in this field, the book provides a critical and comparative analytic framework for understanding Chinese Medicine, Ayurveda, Sowa Rigpa, and Japanese Kampo in the 21st century. No longer subaltern health resources or conservative systems of traditional knowledge, these medicines have become an integral part of modern Asia as innovative, lucrative industries. Ten original case studies employ insights from anthropology, history, geography, pharmaceutical sciences, botany, and economics to trace the transformation of Asian medical traditions into rapidly growing and dynamic pharmaceutical industries. Collectively, these contributions identify this as a major phenomenon impacting Asian and global healthcare, economics, cultural politics, and environments. The book suggests that we can learn more about Asian medicines today by approaching them as industries rather than as cultural or epistemic systems. Asian Medical Industries is a highly original resource for students and scholars across a range of academic fields such as anthropology, history, and Asian studies, as well as medical practitioners, health sector actors, and policymakers.
White Market Drugs
Author | : David Herzberg |
Publisher | : University of Chicago Press |
Total Pages | : 372 |
Release | : 2020-10-23 |
Genre | : History |
ISBN | : 022673191X |
The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer’s Heroin to Purdue’s OxyContin and all the drugs in between: barbiturate “goof balls,” amphetamine “thrill pills,” the “love drug” Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls “white markets,” where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its “drug wars”—until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America’s divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself—ideas that have been failing us catastrophically for over a century.
The Oxford Handbook of the Economics of the Biopharmaceutical Industry
Author | : Patricia M. Danzon |
Publisher | : Oxford University Press |
Total Pages | : 618 |
Release | : 2012-04-12 |
Genre | : Business & Economics |
ISBN | : 0199909261 |
The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with eighteen chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry.
Radioisotopes and Nuclear Techniques in the Pharmaceutical and Allied Industries
Author | : John Edward Christian |
Publisher | : |
Total Pages | : 136 |
Release | : 1960 |
Genre | : Medical radiology |
ISBN | : |
The Changing Economics of Medical Technology
Author | : Institute of Medicine |
Publisher | : National Academies Press |
Total Pages | : 225 |
Release | : 1991-02-01 |
Genre | : Medical |
ISBN | : 030904491X |
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
The Politics of the Pharmaceutical Industry and Access to Medicines
Author | : Hans Löfgren |
Publisher | : Taylor & Francis |
Total Pages | : 370 |
Release | : 2017-07-06 |
Genre | : Family & Relationships |
ISBN | : 1351470604 |
Some papers presented at a conference held at Hyderabad in September 2010.
The Use of Drugs in Food Animals
Author | : National Research Council |
Publisher | : National Academies Press |
Total Pages | : 276 |
Release | : 1999-01-12 |
Genre | : Medical |
ISBN | : 0309175771 |
The use of drugs in food animal production has resulted in benefits throughout the food industry; however, their use has also raised public health safety concerns. The Use of Drugs in Food Animals provides an overview of why and how drugs are used in the major food-producing animal industriesâ€"poultry, dairy, beef, swine, and aquaculture. The volume discusses the prevalence of human pathogens in foods of animal origin. It also addresses the transfer of resistance in animal microbes to human pathogens and the resulting risk of human disease. The committee offers analysis and insight into these areas: Monitoring of drug residues. The book provides a brief overview of how the FDA and USDA monitor drug residues in foods of animal origin and describes quality assurance programs initiated by the poultry, dairy, beef, and swine industries. Antibiotic resistance. The committee reports what is known about this controversial problem and its potential effect on human health. The volume also looks at how drug use may be minimized with new approaches in genetics, nutrition, and animal management.